SciClone Pharma (SCLN) Halted to Announce: Results of Phase 2 SCV-07 Oral Mucositis Trial Won't Meet Efficacy Endpoint
Tweet
Share
E-mailGet Alerts SCLN Hot Sheet
Join SI Premium – FREE
SciClone Pharma (Nasdaq: SCLN) trading halted to announce: interim analysis of Phase 2 SCV-07 oral mucositis trial, says results indicated trial won't meet efficacy endpoint
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Elroy Air wins $46M U.S. Army contract for cargo drone system
- Cytek faces $56M damages award in Beckman Coulter patent case
Create E-mail Alert Related Categories
Corporate News, FDA, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
